Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats

European Journal of Neuroscience

Volumn 12, Issue 6, 2000, Pages 2117-2123

  Bordet, Régis ^a,c   Ridray, Sophie ^b   Schwartz, Jean Charles ^a   Sokoloff, Pierre ^a  

^a CENTRE PAUL BROCA   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIV LILLE   (France)

Author keywords

Dopamine D3 receptor; Parkinson's disease; Preprotachykinin; Prodynorphin

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 3 RECEPTOR; DYNORPHIN; LEVODOPA; MESSENGER RNA; OXIDOPAMINE; PREPROENKEPHALIN; PREPROTACHYKININ; SUBSTANCE P;

ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CONTROLLED STUDY; GENE EXPRESSION; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SENSITIZATION; SUBSTANTIA NIGRA;

EID: 0034078964     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9568.2000.00089.x     Document Type: Article

References (44)

1. 3 receptor as a mechanism of behavioral sensitization to levodopa. Proc. Natl Acad. Sci. USA, 94, 3363-3367.
2. 3 receptor. Neuroscience, 65, 731-745.
3. 2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin. Brain Res., 581, 261-268.
4. 1 dopamine receptors stimulates the release of GABA in the basal ganglia of the rat. Neurosci. Lett., 116, 136-140.
5. Gancher, S.T. (1992) Pharmacology of Parkinson's disease. In Huber, S.T. & Cummings, J.L. (eds), Parkinson's Disease Neurobehavioral Aspects. Oxford University Press, New York, pp. 273-287.
6. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 250, 1429-1432.
7. 1-containing neurons. J. Neurosci., 15, 8167-8176.
8. 1 receptors in drug-naive MPTP monkeys. Brain Res., 719, 129-137.
9. Granata, R., Wenning, G.K., Jolkkonen, J., Jenner, P. & Marsden, C.D. (1996) Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion. J. Neural. Transm., 103, 249-260.
10. 3 receptor: opposite and synergistic interactions with cyclic AMP. J. Neurochem., 67, 1-9.
11. 3H]PD 128907. Psychopharmacology, 128, 240-247.
12. Hardie, R.J. (1990) Levodopa-related motor fluctuations. In Stern, G.M. (eds), Parkinson's Disease. The John Hopkins University Press, Baltimore, USA, pp. 559-596.
13. 1 dopamine receptor in rat brain reveals its axonal transport, pre-and post-synaptic localization, and prevalence in the basal ganglia, limbic system and thalamic reticular nucleus. Proc. Natl Acad. Sci. USA, 89, 11 988-11 992.
14. 3 receptor expression within the basal ganglia is not effected by Parkinson's disease. Neurosci. Lett., 214, 75-78.
15. Innis, R.B., Andrade, R. & Aghajanian, G.K. (1985) Substance K excites dopaminergic and non-dopaminergic neurons in rat substantia nigra. Brain Res., 335, 381-383.
16. 2 receptors mediate the behavioral effects of dopamine agonists. Behav. Brain Res., 38, 233-242.
17. 2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. Comp. Neurol., 355, 418-426.
18. 2 dopamine receptors. Neuroscience, 73, 131-143.
19. 2 receptor, substance P and enkephalin messenger RNAs in the neurons projecting from the nucleus accumbens. Neuroscience, 82, 767-780.
20. Matsuda, H., Hiyama, Y., Terasawa, K., Watanabe, H. & Matsumoto, K. (1992) Enhancement of rotational behavior induced by repeated administration of SKF38393 in rats with unilateral nigrostriatal 6-OHDA lesions. Pharmacol. Biochem. Behav., 42, 213-218.
21. 3 receptors: effects of MPTP and dopamine agonist replacement therapies. Eur. J. Neurosci., 10, 2565-2573.
22. 2 receptor agonists. J. Neurochem., 72, 682-692.
23. Mouradian, M.M., Juncos, J.L., Fabbrini, G. & Chase, T.N. (1987) Motor fluctuations in Parkinson's disease: pathogenic and therapeutic studies. Ann. Neurol., 22, 475-479.
24. Paxinos, G. & Watson, C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn, Academic Press, New York.
25. 3 receptor agonist. Nature, 400, 371-375.
26. Pinheiro-Carrera, M., Tomaz, V., Huston, J.P. & Carey, R.J. (1995) NMDA antagonist effects on the development of L-dopa behavioral sensitization in rats. Behav. Neurosci., 109, 34-42.
27. 1 receptor-dependent cyclic AMP production in striatal tissue. Eur. J. Pharmacol., 331, 23-26.
28. Pinnock, R.D. & Dray, A. (1982) Differential sensitivity of presumed dopaminergic and non-dopaminergic neurones in rat substantia nigra to electrophoretically applied substance P. Neurosci. Lett., 29, 153-158.
29. 3 receptors in rat ventral striatum: opposite and synergistic functional interactions. Eur. J. Neurosci., 10, 1676-1686.
30. Rinne, U.K. & Rinne, J.O. (1989) Treatment of early Parkinson's disease with controlled-release levodopa preparations. Neurology, 39, 78-81.
31. Robertson, H.A. (1992) Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci., 15, 201-206.
32. Robertson, G.S. & Robertson, H.A. (1988) Evidence that the substantia nigra is a site of action for L-DOPA. Neurosci. Lett., 89, 204-209.
33. Robertson, G.S. & Robertson, H.A. (1989) Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J. Neurosci., 9, 3326-3331.
34. 2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord, 13, 788-797.
35. 3H]SCH 23390 binding sites in pars reticulata and pars compacta of the substantia nigra in the rat. Neurosci. Lett., 72, 265-271.
36. 1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior. Brain Res., 23, 119-130.
37. 3H]aminobutyric acid release? J. Neurochem., 49, 1042-1049.
38. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res., 779, 58-74.
39. Tagliamonte, A., Gambarano, C. & De Montis, M.G. (1999) NMDA receptor-dependent and -independent behavioral sensitization. Trends Pharmacol. Sci., 20, 187-188.
40. Tzschentke, T.M. & Schmidt, W.J. (1998) Does the noncompetitive NMDA receptor antagonist dizocilpine (MK 801) really block behavioral sensitization associated with repeated drug administration. Trends Pharmacol. Sci., 19, 447-451.
41. 1-receptor agonist. Brain Res. Mol. Brain Res., 61, 219-223.
42. Wolf, M.E. (1999) NMDA receptors and behavioral sensitization: beyond dizocilpine. Trends Pharmacol. Sci., 20, 188-189.
43. 1 receptors in striatal fos protein induction associated with methamphetamine behavioral sensitization in rats. Brain Res. Bull., 38, 393-397.
44. 2 receptor agonists. Neuroscience, 63, 427-434.